The Drug Abuse Screening Test (DAST): First 40 Years and Future Developments DOI
Harvey A. Skinner, Sarah Samadi,

Sirkhail Khan

et al.

The Canadian Journal of Addiction, Journal Year: 2024, Volume and Issue: 15(4), P. 6 - 13

Published: Dec. 1, 2024

ABSTRACT Since the original article was published over 40 years ago, Drug Abuse Screening Test (DAST) developed at Centre for Addiction and Mental Health—CAMH, Toronto (www.camh.ca/) has become one of most widely used addiction instruments in North America internationally population clinical screening, assessment, research a broad range settings. The developmental prototype contained 28 items (DAST-28) from which 2 versions were derived: 10-item DAST-10 screening more comprehensive 20-item DAST-20 assessment research. first aim this commentary review is to highlight recent trends wide-ranging use on DAST. international reach exemplified by 18 (currently) translations cultural adaptations. Research shown that DAST exhibits high levels reliability validity across public health settings, it as benchmark validation studies other measures. recommended instrument national agencies an evidence-based tool, example, https://cde.nida.nih.gov/. To address evolving contextual shifts, especially imperative reduce stigma, second introduce revised designated DAST-10-R DAST-20-R, incorporate recommendations NIDA’s (2021) Words Matter—Terms Use Avoid When Talking About Addiction. A feasibility study described community center. Future directions are outlined, including calibration DAST-R with evaluating utilization spectrum health, community, Depuis la publication de l’article il y plus ans, le mis au point par Health - CAMH, est devenu l’un des les utilisés en Amérique du Nord et dans monde pour dépistage, l'évaluation recherche milieu clinique un large éventail contextes. Le développement contenait à partir desquels deux ont été dérivées : 10 dépistage 20 items, complet, recherche. premier objectif ce commentaire mettre évidence tendances récentes l’utilisation grande échelle La portée internationale illustrée ses traductions (actuelles) adaptations culturelles. montré que présente niveaux élevés fiabilité validité toute une série contextes cliniques santé publique, qu’il utilisé comme référence études d’autres mesures. recommandé agences nationales tant qu’outil fondé sur données probantes exemple, Pour tenir compte l'évolution contexte, particulier l’impératif réduction stigmatisation, deuxième présenter révisées désignées qui intègrent recommandations rapport NIDA Matter Terms . Une étude faisabilité centre communautaire décrite. Les orientations futures sont présentées, compris l'étalonnage avec travers spectre communauté environnements cliniques.

Language: Английский

Proper counseling for diagnosis and management of cannabinoid hyperemesis syndrome: a case report DOI

Samuel Cholette-Tétrault,

Roland Grad

Family Practice, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 20, 2024

Abstract Background Cannabinoid hyperemesis syndrome (CHS) is an increasingly recognized condition linked to chronic cannabis use, yet it remains frequently overlooked in clinical practice. The characterized by cyclic episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily hot showers or baths. With the rising prevalence use following its legalization, incidence CHS has surged, presenting a significant challenge both diagnosis management within primary healthcare settings. Understanding epidemiology, risk factors, potential long-term sequelae crucial for timely identification intervention. This case report highlights healthcare. Objective(s) To emphasize importance proper counseling Rome IV criteria diagnosing CHS. illustrate how this may reduce patient suffering unnecessary investigation. Case A 22-year-old female with chronic, daily presented recurrent intense pain over 2-year period. Extensive diagnostic evaluations were inconclusive. tentative was made medical student family doctor based on published criteria. then applied confirmation management. In so doing, advised cease minimum 3 months. Initially, symptom improvement reported cessation. However, symptoms recurred relapse use. Conclusion confirm CHS, should specify need months cessation achieve relief. Increased physician awareness minimal time period drug can help avoid investigations, prolonged suffering. emphasizes vigilance recognizing consideration as cause vomiting.

Language: Английский

Citations

0
TheCannabis Act: implications for human participant research with cannabis DOI Open Access
Patricia Di Ciano, Christine M. Wickens,

Elvin M. Paul

et al.

Journal of Psychiatry and Neuroscience, Journal Year: 2024, Volume and Issue: 49(3), P. E212 - E217

Published: June 18, 2024

In Canada, cannabis was legalized for medical purposes in 2001 and nonmedical use 2018, with edibles, concentrates, topicals following 2019 under the Canadian Cannabis Act (Bill C-45).[1][1] This legislation regulates production, distribution, sale, possession of cannabis,

Language: Английский

Citations

0
The Drug Abuse Screening Test (DAST): First 40 Years and Future Developments DOI
Harvey A. Skinner, Sarah Samadi,

Sirkhail Khan

et al.

The Canadian Journal of Addiction, Journal Year: 2024, Volume and Issue: 15(4), P. 6 - 13

Published: Dec. 1, 2024

ABSTRACT Since the original article was published over 40 years ago, Drug Abuse Screening Test (DAST) developed at Centre for Addiction and Mental Health—CAMH, Toronto (www.camh.ca/) has become one of most widely used addiction instruments in North America internationally population clinical screening, assessment, research a broad range settings. The developmental prototype contained 28 items (DAST-28) from which 2 versions were derived: 10-item DAST-10 screening more comprehensive 20-item DAST-20 assessment research. first aim this commentary review is to highlight recent trends wide-ranging use on DAST. international reach exemplified by 18 (currently) translations cultural adaptations. Research shown that DAST exhibits high levels reliability validity across public health settings, it as benchmark validation studies other measures. recommended instrument national agencies an evidence-based tool, example, https://cde.nida.nih.gov/. To address evolving contextual shifts, especially imperative reduce stigma, second introduce revised designated DAST-10-R DAST-20-R, incorporate recommendations NIDA’s (2021) Words Matter—Terms Use Avoid When Talking About Addiction. A feasibility study described community center. Future directions are outlined, including calibration DAST-R with evaluating utilization spectrum health, community, Depuis la publication de l’article il y plus ans, le mis au point par Health - CAMH, est devenu l’un des les utilisés en Amérique du Nord et dans monde pour dépistage, l'évaluation recherche milieu clinique un large éventail contextes. Le développement contenait à partir desquels deux ont été dérivées : 10 dépistage 20 items, complet, recherche. premier objectif ce commentaire mettre évidence tendances récentes l’utilisation grande échelle La portée internationale illustrée ses traductions (actuelles) adaptations culturelles. montré que présente niveaux élevés fiabilité validité toute une série contextes cliniques santé publique, qu’il utilisé comme référence études d’autres mesures. recommandé agences nationales tant qu’outil fondé sur données probantes exemple, Pour tenir compte l'évolution contexte, particulier l’impératif réduction stigmatisation, deuxième présenter révisées désignées qui intègrent recommandations rapport NIDA Matter Terms . Une étude faisabilité centre communautaire décrite. Les orientations futures sont présentées, compris l'étalonnage avec travers spectre communauté environnements cliniques.

Language: Английский

Citations

0